SOM3355
Huntington's disease
Key Facts
About SOM Biotech
SOM Biotech is a Spanish biotech leveraging its proprietary AI platform, SOMaiPRO®, to accelerate drug discovery for rare CNS conditions with high unmet need. The platform has demonstrated strong clinical predictivity, with two identified compounds achieving positive Phase 2a proof-of-concept results. The company's lead program, SOM3355 for Huntington's disease, is poised to enter Phase 3, positioning SOM Biotech as a late-stage clinical development entity. Its strategy combines AI-driven discovery with deep clinical expertise to build a targeted pipeline in valuable, underserved neurological and psychiatric markets.
View full company profileAbout SOM Biotech
SOM Biotech is a Spanish biotech leveraging its proprietary AI platform, SOMaiPRO®, to accelerate drug discovery for rare CNS conditions with high unmet need. The platform has demonstrated strong clinical predictivity, with two identified compounds achieving positive Phase 2a proof-of-concept results. The company's lead program, SOM3355 for Huntington's disease, is poised to enter Phase 3, positioning SOM Biotech as a late-stage clinical development entity. Its strategy combines AI-driven discovery with deep clinical expertise to build a targeted pipeline in valuable, underserved neurological and psychiatric markets.
View full company profileTherapeutic Areas
Other Huntington's disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| Huntington's Disease Program | Rumi Scientific | Pre-clinical |
| LETI-101 | ElevateBio | Preclinical |
| Somatic Expansion Inhibitor Program | LoQus23 Therapeutics | Preclinical |
| Preclinical Program | Excision BioTherapeutics | Preclinical |
| NA-841 | Biomed | Phase 2A |
| T3D-959 (Future) | T3D Therapeutics | Pre-clinical / Research |
| HD mAb Therapy | HD Immune | Pre-clinical |
| TT-P34 | Teitur Trophics | Pre-clinical |
| INT41 | Vybion | Pre-clinical |
| Huntington's Program | reMYND | Pre-clinical |
| Pridopidine | Prilenia Therapeutics | Phase 3 |